The present study demonstrated that KOB03 has therapeutic potential in AR by inhibiting nasal obstruction and the release of inflammatory mediators such as histamine, allergen-specific IgE, and ECP and modulating the imbalance of Th1/Th2 cytokines in OVA sensitization/challenge-induced AR guinea pigs. This evidence concerns the gene RNASE3 and Nasal congestion.